Dianthus initiated with a Buy at Stifel

Stifel analyst Alex Thompson initiated coverage of Dianthus (DNTH) with a Buy rating and $44 price target. The firm’s thesis is based on the view that inhibition of the Classical Complement Pathway has the potential to drive meaningful clinical benefit across auto-antibody mediated diseases and that the company’s lead candidate, DNTH103, is designed to improve upon Sanofi’s (SNY) C1s inhibitor, Riliprubart, the analyst tells investors. Following a recent financing, Dianthus has a cash runway to the second half of 2027, the analyst added.